# Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

> **NCT02752685** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 70 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT02752685
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-06
- **Primary completion:** 2022-12-29
- **Final completion:** 2025-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02752685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02752685, "Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02752685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*